What is Vertex Pharmaceuticals's common stock, shares authorized (in shares)?

Vertex Pharmaceuticals (VRTX) reported common stock, shares authorized (in shares) of 500M in Q1 2026.

How has Vertex Pharmaceuticals's common stock, shares authorized (in shares) changed year-over-year?

Vertex Pharmaceuticals's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from 500M to 500M.

What is the long-term trend for Vertex Pharmaceuticals's common stock, shares authorized (in shares)?

Over 5 years (2020 to 2025), Vertex Pharmaceuticals's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from 500M to 500M.

What does common stock, shares authorized (in shares) mean?

The maximum number of shares the company is allowed to issue to the public.

Other

Common stock, shares authorized (in shares)

Vertex Pharmaceuticals Common stock, shares authorized (in shares) remained flat by 0.0% to 500M in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from 500M to 500M. Over 5 years (FY 2020 to FY 2025), Common stock, shares authorized (in shares) shows relatively stable performance with a 0.0% CAGR.

Analysis

StatementBalance Sheet Statement

SectionOther

CategoryCapital Allocation

SignalContext dependent

VolatilityStable

First reportedQ4 2015

Last reportedQ1 2026May 5, 2026

How to read this metric

An increase in authorized shares often signals potential future capital raising or stock split activity.

Detailed definition

This is the maximum number of shares that a company is legally permitted to issue according to its corporate charter. It...

Peer comparison

Standard corporate governance metric; usually set significantly higher than issued shares to provide flexibility.

Metric ID: other_common_stock_shares_authorized

Historical Data

20 periods

	Q2 '21	Q3 '21	Q4 '21	Q1 '22	Q2 '22	Q3 '22	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	500M	500M	500M	500M	500M	500M	500M	500M	500M	500M	500M	500M	500M	500M	500M	500M	500M	500M	500M	500M
QoQ Change	—	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%
YoY Change	—	—	—	—	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%

Range500M – 500M

CAGR+0.0%

Avg YoY Growth+0.0%

Median YoY Growth+0.0%

Current Streak19+ quarters growth

Common stock, shares authorized (in shares) at Other Companies

AbbVieABBV View metric

Merck & Co.MRK View metric

Roivant SciencesROIV View metric

ViatrisVTRS View metric

ALN

Alnylam PharmaceuticalsALNY View metric

AmgenAMGN View metric

Frequently Asked Questions

What is Vertex Pharmaceuticals's common stock, shares authorized (in shares)?: Vertex Pharmaceuticals (VRTX) reported common stock, shares authorized (in shares) of 500M in Q1 2026.
How has Vertex Pharmaceuticals's common stock, shares authorized (in shares) changed year-over-year?: Vertex Pharmaceuticals's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from 500M to 500M.
What is the long-term trend for Vertex Pharmaceuticals's common stock, shares authorized (in shares)?: Over 5 years (2020 to 2025), Vertex Pharmaceuticals's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from 500M to 500M.
What does common stock, shares authorized (in shares) mean?: The maximum number of shares the company is allowed to issue to the public.